All Updates

All Updates

icon
Filter
Funding
Senti Biosciences receives USD 8 million CIRM grant to develop CAR-NK cell therapy
Cell & Gene Therapy
Jul 1, 2024
This week:
Partnerships
Sheeva.AI and P97 Networks partner for in-car payment solutions at fuel stations
Auto Tech
Today
Product updates
Food Cycle Science launches 'Food Cycler Eco 3,' a household food waste processing bin
Food Waste
Yesterday
Partnerships
Von Holzhausen and Herman Miller partner to launch plant-based leather Eames Chair
Bio-based Materials
Yesterday
Partnerships
Volvo Cars partners with Beijing Shougang and Zhejiang Yiyun for automotive steel recycling
Waste Recovery & Management Tech
Yesterday
Funding
LanzaJet receives strategic investment from Airbus
Carbon Capture, Utilization & Storage (CCUS)
Yesterday
Funding
LanzaJet receives strategic investment from Airbus
Alternative Energy
Yesterday
Partnerships
Odie Pet Insurance partners with Insuritas to offer pet coverage through financial institutions
Pet Care Tech
Yesterday
Partnerships
Odie Pet Insurance partners with Insuritas to offer pet coverage through financial institutions
InsurTech: Personal Lines
Yesterday
M&A
Applied Systems acquires Planck for undisclosed sum to expand AI capabilities
InsurTech: Infrastructure
Yesterday
Product updates
Monzo launches pension consolidation product
Neobanks
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

Jul 1, 2024

Senti Biosciences receives USD 8 million CIRM grant to develop CAR-NK cell therapy

Funding

  • CAR-T therapy developer Senti Biosciences has secured USD 8 million in grant funding from the California Institute for Regenerative Medicines (CIRM) to accelerate the development of Senti's chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy SENTI-202.

  • The funds will fuel the ongoing Phase I clinical trial of SENTI-202 aimed at treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The initial efficacy data of the trial is to be ready by late 2024 and initial durability data by 2025.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.